Podolanczuk AJ, Cottin V. A narrative review of real-world data on the safety of nintedanib in patients with idiopathic pulmonary fibrosis. Adv Ther. 2023;40(5):2038-2050. doi:10.1007 ...

Boehringer Ingelheim was given the opportunity to review the article for medical ... Raghu G, Remy-Jardin M, Richeldi L, et al. Idiopathic pulmonary fibrosis (an update) and progressive pulmonary ...

The Network successfully integrated into traditional TANF and addresses SDH through peer-group programming where caregivers heal from adversity and build financial skills. We identify three challenges ...

The Program for Pulmonary Fibrosis ... reviewed, including any prior biopsies, you will receive either a letter from one of our physicians or a copy the patient's clinic visit note. The UAB ILD Center ...

Idiopathic pulmonary fibrosis is a chronic, progressive, incurable lung disease, leading to irreversible lung tissue ...

After initial checks are complete, the manuscript is assigned to an editor, who reads the paper, consults with the editorial team, and decides whether it should be sent for peer review.

You can select ‘I Accept’ to consent to these uses or click on ‘Manage preferences’ to review your options and exercise your right to object to Legitimate Interest where used. You can change your ...

Radiologists play an important role in the assessment and management of pulmonary hypertension. A working group was formed to address key questions related to the utility of imaging for the ...

The Program for Pulmonary Fibrosis ... reviewed, including any prior biopsies, you will receive either a letter from one of our physicians or a copy the patient's clinic visit note. The UAB ILD Center ...

The Editor-in-Chief must approve all accept and reject decisions, except when away or recused from peer review. Authors can expect to learn of a decision on their paper approximately 4 weeks after ...